The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients - Wikidata - wikimedia - TriplyDB

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients

http://www.wikidata.org/entity/Q37293650

about

Safety and efficacy of telbivudine for the treatment of chronic hepatitis B Development of fatal acute liver failure in HIV-HBV coinfected patients.HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches.Safety and efficacy of entecavir for the treatment of chronic hepatitis B.Management of chronic hepatitis B in patients from special populations HIV/HBV coinfection in children and antiviral therapy.Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.Future directions in the treatment of HIV-HBV coinfection.New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo.Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.Management of HIV and hepatitis virus coinfection.Treatment of special populations with chronic hepatitis B infection.Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase.

P2860

Q28972486-66694F7D-514A-4894-B278-9FD5E77FBB0C Q34084999-9F50A8C3-07FA-4C16-9340-0CD02368E8F9 Q34966832-DF19A8BF-0516-4570-BB49-45923EEB78F6 Q35026611-B5CA3492-A091-4F06-A31A-0128A486E4CD Q35664183-DCA8D9EB-68D7-4BB7-9668-4D89059367FF Q36775147-15D7E3B8-6DB9-48D8-8970-3E4275C2A0A5 Q37291331-FFDD7D41-AEE0-4F15-9220-145E6334E642 Q37439933-63199808-E19C-44CA-A3D1-C0F6BE915663 Q37617931-315B14F4-FB3B-4998-91BD-5675DB5C3E93 Q37678183-DCBE6521-0AAE-43BA-BC72-90733FDAF485 Q37762108-0FFA9574-C572-46D7-ADD6-BA100DBEB1CB Q37772508-5283382C-7379-4AA1-BA6E-775D4274AB19 Q37886158-46FB7C5A-CD1B-4B93-967D-45875A4CCCD9 Q41503130-56F897DC-ED19-4A76-AF80-C52E175A59D5

P2860

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients

http://www.wikidata.org/entity/Q37293650

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The anti-HIV activity of entec ...... and lamivudine-naive patients

@en

The anti-HIV activity of entec ...... and lamivudine-naive patients.

@nl

type

label

The anti-HIV activity of entec ...... and lamivudine-naive patients

@en

The anti-HIV activity of entec ...... and lamivudine-naive patients.

@nl

prefLabel

The anti-HIV activity of entec ...... and lamivudine-naive patients

@en

The anti-HIV activity of entec ...... and lamivudine-naive patients.

@nl

P1433

Q37293650-7D9BBC3A-A876-4C75-ADA3-86F1A2393B06

P1476

Q37293650-C23E9473-28DF-42B6-9690-2ABBDE0E34F6

P2093

Q37293650-57295375-9D82-40BC-814F-5773540BD0BB

Q37293650-5BC92B32-B9D4-44E8-AC93-6CD306411DC1

Q37293650-7240F523-ACF7-49B9-B317-7FAAD2A262A2

Q37293650-7C5694D6-B749-427E-B95B-77C576FDD1F6

Q37293650-8D3AF118-0528-4BC8-9C43-AF2CE9B136BF

Q37293650-8FEDD07A-8903-4A3E-9A74-103D52D834BE

Q37293650-B51938F1-584E-42E7-A998-5FB967D48B21

Q37293650-E4768583-D4DE-4402-B24F-55D487A61892

Q37293650-E4D41023-010F-4956-904E-C0BD43137377

P2860

Q37293650-0AB53DC5-5846-4C40-B253-44105A60A677

Q37293650-12F7A66B-7031-4CE7-A4FD-F267D382FA4D

Q37293650-200360F4-36BE-4A68-9F1F-7311FA4BAA61

Q37293650-254F2FF8-32CC-41AB-9ECA-70644F44BEBE

Q37293650-4DEFBF71-186A-4905-82DF-366A5BDF285D

Q37293650-5CAF86AB-3C20-4611-87F0-00E8D9C5C01B

Q37293650-6C024062-8E2C-47DA-BB06-08063731FC78

Q37293650-8552A149-9F1C-4F83-AA76-98670759FC02

Q37293650-8A968890-C741-4583-8688-1EF30BF3A361

Q37293650-8D6BB742-6E2E-409D-B772-B2846EA17659

P304

Q37293650-16AF8212-BAC9-435E-B102-6AC301B9C3F6

P31

Q37293650-B1A6AB06-EF0E-40AD-8F3C-2BAE211075B9

P356

Q37293650-A7841865-7B9E-440E-A7D0-9DF4B1FBD1A1

P407

Q37293650-570F409C-7CE4-4003-A6E5-9DD5A5177ACD

P433

Q37293650-DD7093B8-F7BF-4761-B95D-E930985BA615

P478

Q37293650-0664E263-BB2F-40CC-B138-5BC735849F07

P50

Q37293650-6B8B2824-D4E4-48A4-A754-45E4C1FD66A7

Q37293650-9471F59E-F5E9-4175-B7D0-299194CF042D

Q37293650-BFF5C888-B670-4829-BE91-4F0E747F9C5C

P577

Q37293650-72DA6095-D6D7-4FFE-9968-150B2A40101F

P5875

Q37293650-C34272DC-DF63-4C3A-A1D2-8BB71B8D788E

P698

Q37293650-A7F2A5D1-C33A-4943-84DD-F1546AD2B114

P921

Q37293650-CF840E83-B589-41A6-B3EA-9E47083CE874

P932

Q37293650-1888254B-C22A-44D6-9CE6-2A77C0F38D30

P356

QAD.0B013E3282FFDE91

P1433

P1476

The anti-HIV activity of entec ...... and lamivudine-naive patients

@en

P2093

Anne Mijch

http://www.w3.org/2001/XMLSchema#string

Chloe L Thio

http://www.w3.org/2001/XMLSchema#string

Gail Matthews

http://www.w3.org/2001/XMLSchema#string

Hermeyone Hunter

http://www.w3.org/2001/XMLSchema#string

Joe Sasadeusz

http://www.w3.org/2001/XMLSchema#string

Jose Caro

http://www.w3.org/2001/XMLSchema#string

Moira A McMahon

http://www.w3.org/2001/XMLSchema#string

Rachel Baden

http://www.w3.org/2001/XMLSchema#string

Susan A Olender

http://www.w3.org/2001/XMLSchema#string

P2860

Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

Chronic hepatitis B.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

The HBV drug entecavir - effects on HIV-1 replication and resistance

Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.

Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects.

Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases.

P304

947-955

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E3282FFDE91

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Sharon R. Lewin

Jennifer Audsley

Robert F. Siliciano

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5398617

http://www.w3.org/2001/XMLSchema#string

P698

18453854

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

2722443

http://www.w3.org/2001/XMLSchema#string